CN105792828A - 使用莫米松和奥洛他定的组合治疗过敏性鼻炎 - Google Patents

使用莫米松和奥洛他定的组合治疗过敏性鼻炎 Download PDF

Info

Publication number
CN105792828A
CN105792828A CN201480066538.0A CN201480066538A CN105792828A CN 105792828 A CN105792828 A CN 105792828A CN 201480066538 A CN201480066538 A CN 201480066538A CN 105792828 A CN105792828 A CN 105792828A
Authority
CN
China
Prior art keywords
olopatadine
salt
composition
treatment
mometasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480066538.0A
Other languages
English (en)
Chinese (zh)
Inventor
N·凯拉特卡尔裘西
A·库尔卡尼
D·P·瓦勒
V·M·博萨勒
P·阿加瓦尔
P·基奥恩
S·K·坦特里
C·欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grand Mark
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Priority to CN202110299649.8A priority Critical patent/CN112773808A/zh
Publication of CN105792828A publication Critical patent/CN105792828A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480066538.0A 2013-10-04 2014-10-03 使用莫米松和奥洛他定的组合治疗过敏性鼻炎 Pending CN105792828A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110299649.8A CN112773808A (zh) 2013-10-04 2014-10-03 使用莫米松和奥洛他定的组合治疗过敏性鼻炎

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
IN3174MUM2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110299649.8A Division CN112773808A (zh) 2013-10-04 2014-10-03 使用莫米松和奥洛他定的组合治疗过敏性鼻炎

Publications (1)

Publication Number Publication Date
CN105792828A true CN105792828A (zh) 2016-07-20

Family

ID=51982657

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480066538.0A Pending CN105792828A (zh) 2013-10-04 2014-10-03 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
CN202110299649.8A Pending CN112773808A (zh) 2013-10-04 2014-10-03 使用莫米松和奥洛他定的组合治疗过敏性鼻炎

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110299649.8A Pending CN112773808A (zh) 2013-10-04 2014-10-03 使用莫米松和奥洛他定的组合治疗过敏性鼻炎

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553A1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN105792828A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787954A (zh) * 2018-02-23 2020-10-16 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
CN115444851A (zh) * 2017-06-28 2022-12-09 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
AU7859800A (en) 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
PL376970A1 (pl) * 2002-11-12 2006-01-23 Alcon, Inc. Zastosowanie środka przeciwalergicznego i steroidu do leczenia alergicznego nieżytu nosa
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2586553C (en) 2004-11-24 2015-02-10 Alcon, Inc. Nasal sprayer containing a formulation with olopatadine
SI1919450T1 (sl) * 2005-09-01 2014-10-30 Meda Ab Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
WO2007064912A2 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
WO2007123193A1 (ja) 2006-04-21 2007-11-01 Toko Yakuhin Kogyo Kabushiki Kaisha スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
KR20110045004A (ko) * 2008-07-15 2011-05-03 쉐링 코포레이션 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
CN102470099A (zh) 2009-07-17 2012-05-23 爱尔康研究有限公司 儿童用奥洛他定鼻腔喷雾方案
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
EP2736491B1 (en) 2011-01-04 2017-04-05 Bausch & Lomb Incorporated Bepotastine compositions
BR112015009087A2 (pt) 2012-10-25 2017-11-14 Novozymes As método para lavagem de louça manual, e, composição detergente
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
PH12016500433B1 (en) 2013-09-13 2023-03-01 Glenmark Pharmaceuticals Ltd Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444851A (zh) * 2017-06-28 2022-12-09 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物
CN111787954A (zh) * 2018-02-23 2020-10-16 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎

Also Published As

Publication number Publication date
RU2686670C2 (ru) 2019-04-30
EP4272839A2 (en) 2023-11-08
JP2018123157A (ja) 2018-08-09
US20150099725A1 (en) 2015-04-09
PH12015502302B1 (en) 2016-02-15
JP2020097624A (ja) 2020-06-25
WO2015049665A1 (en) 2015-04-09
EP4272839A3 (en) 2024-01-03
RU2015128496A (ru) 2017-11-13
PH12015502302A1 (en) 2016-02-15
RU2019104453A (ru) 2019-03-28
US10646500B2 (en) 2020-05-12
HK1215674A1 (zh) 2016-09-09
RU2015128496A3 (enExample) 2018-06-19
MX2020003035A (es) 2020-07-22
EP2922553A1 (en) 2015-09-30
JP2016531949A (ja) 2016-10-13
ZA201504740B (en) 2016-10-26
JP6419195B2 (ja) 2018-11-07
MY176808A (en) 2020-08-21
UA120587C2 (uk) 2020-01-10
MX2015009429A (es) 2015-10-09
CN112773808A (zh) 2021-05-11
JP6768733B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
CN105792828A (zh) 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
KR101873174B1 (ko) 날록손을 포함하는 비강내 제약 투여 형태
CA2460140C (en) Compositions for treatment of common cold
JP2022088592A (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US9844580B2 (en) Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
JP6762931B2 (ja) 経鼻組成物と該経鼻組成物の使用方法の改善
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
WO2010025236A1 (en) Composition and method for treating colds
US10548907B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US20240408004A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
JP2014515360A (ja) フルチカゾンを含む鼻用医薬製剤
AU2019403368A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
Li et al. Efficacy of montelukast as prophylactic treatment for seasonal allergic rhinitis
HK40095786A (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
RU2799761C2 (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
CN115487180A (zh) 一种用于治疗变应性鼻炎的药物组合物
Neerati A textbook of pharmacology-III
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
RU2781144C2 (ru) Усовершенствование назальных композиций и способ их использования
MX2014003546A (es) Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170309

Address after: La Chaux-de-Fonds

Applicant after: Grand Mark

Address before: Mumbai

Applicant before: Glenmark Pharmaceuticals Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160720